Notice of Special Interest: National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Control and Population Sciences
Notice Number:

Key Dates

Release Date:

December 20, 2023

First Available Due Date:
February 12, 2024
Expiration Date:
May 08, 2029

Related Announcements

  • December 21, 2023 - Notice of NCI’s Participation in NIH Mentored Research Scientist Development Awards (Parent K01) Notices of Funding Opportunity. See NOT-CA-24-020
  • May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required). See NOFO PA-20-176
  • May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed). See NOFO PA-20-190
  • May 6, 2020 - Mentored Research Scientist Development Award (Parent K01 - Independent Basic Experimental Studies with Humans Required). See NOFO PA-20-191

Issued by

National Cancer Institute (NCI)


This Notice of Special Interest (NOSI) from the National Cancer Institute (NCI) invites applications from early career scientists conducting research within the mission of the Division of Cancer Control and Population Sciences for the Mentored Research Scientist Development Award (K01).


The mission of NCI's Division of Cancer Control and Population Sciences (DCCPS) is to advance research in cancer control and population sciences to eliminate cancer and its consequences for all.

Cancer control science is defined as basic and applied research in the behavioral, social, and population sciences to create or enhance interventions that, independently or in combination with biomedical approaches reduce cancer risk, incidence, morbidity, and mortality, and improve quality of life. DCCPS has several broad areas of interest: development and validation of methods, technologies, and tools in surveillance, statistics, epidemiology, health care delivery, and the behavioral sciences; identification of modifiable risk factors or host susceptibility factors associated with cancer etiology, cancer prevention, and treatment outcomes; and clinical and translational science to reduce risk, incidence, and death from cancer, as well as enhance the quality of life for cancer survivors. DCCPS also has an interest in cross-cutting themes, health disparities and health equity , implementation science , and cancer survivorship .

To this end, the NCI Cancer Training Branch in the Center for Cancer Training and DCCPS are issuing this announcement to allow applications from early-career scientists conducting research within the mission of DCCPS to the K01 Mentored Career Development Award funding opportunities.


Priority research areas for DCCPS include but are not limited to:

DCCPS is interested promoting training in scientific areas such as:

  • Population level studies aimed at understanding the determinants of cancer incidence and outcomes, with the goal of translating discoveries into clinical and public health interventions across diverse populations.
  • Identification and understanding of personal susceptibility factors such as genetic, epigenetic, immunological, inflammation and hormonal biological pathways, and social, cultural, and race/ethnic factors; characterizing factors to reduce cancer risk in humans, including exposures to physical and chemical agents; social and behavioral built environments; nutritional components; physical activity and energy balance; and infectious agents.
  • Behavioral studies that focus on key psychological, social, behavioral, and biobehavioral targets across the cancer control continuum, from prevention to end-of-life care in general, high risk, underserved, and survivor populations.
  • Research and training projects including basic behavioral and psychosocial science fundamental to understanding human behaviors, socioecological context, information seeking and decision-making, and clinical practices associated with cancer prevention and control; interventions to improve cancer-related health behaviors such as tobacco use, alcohol use, diet and energy balance, physical activity and sedentary behaviors, sun safety, sleep and circadian dysfunction, cannabis, and emerging and co-occurring cancer risk behaviors, that target all levels of influence from individual, dyadic, family, community, built and social environment and policy; and patient-centered communication including the impact of technology on health communication, equity in communication, and the translation of health communication research into public health and clinical practice.
  • Health care delivery research that focuses on the study of cancer care, multilevel factors influencing care, and outcomes of care. Cancer care refers to medical services offered across the cancer continuum, such as screening individuals not known to have cancer; treating cancer patients; following cancer survivors for recurrence or new cancers; and providing psychosocial support for patients and their caregivers.
  • Surveillance research that focuses on developing analytical tools and methodologies in collecting, interpreting, and disseminating population-based cancer statistics in the US. Cancer surveillance provides a quantitative portrait of cancer and its determinants in a defined population.
  • Research that will enhance the quality and/or length of survival for persons diagnosed with cancer or that will prevent, minimize, or manage adverse effects of cancer and its treatment.
  • Implementation science that focuses on strategies to influence equitable adoption, implementation, sustainment and scale-up of evidence-based cancer control interventions, considers adaptation of interventions and settings to optimize uptake and impact of interventions, and (where indicated) de-implementation of ineffective or harmful interventions. Evidence-based cancer control interventions refer to the collection of research-tested practices and programs across the cancer continuum shown to benefit cancer-related outcomes.

Application and Submission Information

This notice applies to due dates on or after February 12, 2024 and subsequent receipt dates until further notice. Submit applications for this initiative using the following notices of funding opportunity (NOFOs) or any reissues of these NOFOs.

  • PA-20-176 - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required)
  • PA-20-190: - Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed)
  • PA-20-191 - Mentored Research Scientist Development Award (Parent K01 - Independent Basic Experimental Studies with Humans Required)

All instructions in the SF424 (R&R) Application Guide and the NOFO used for submission must be followed, with the following additions:

  • For funding consideration, applicants must include NOT-CA-24-022" (without quotation marks) in the Agency Routing Identifier field (Box 4b) of the SF424 R&R form. Applications without this information in Box 4b will not be accepted.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.


Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity.

Scientific/Research Contact(s)

For questions related to the Division of Cancer Control and Population Sciences research interests

April Oh, PhD, MPH

National Cancer Institute (NCI)
Telephone: 240-753-3154

For questions related to the NCI K01 Mentored Research Scientist Development Award

Sergey Radaev, PhD

National Cancer Institute (NCI)
Telephone: 240-276-5630

Peer Review Contact(s)

Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s)

Amy Bartosch

National Cancer Institute
Telephone: 240-276-6375